Advertisement
Original Study|Articles in Press

Tumor Volume is a Better Prognostic Factor than Greatest Tumor Diameter in operated Stage I-III Non-small Cell Lung Cancer

Published:March 04, 2023DOI:https://doi.org/10.1016/j.cllc.2023.02.009
      • In the conventional TNM system only the great tumor diameter is taken into account to describe tumor size
      • Tumors do not always have a uniform shape and GTD can't always completely describe the true size of tumor especially which was irregular.
      • We suggest the hypotesis that TV might reflect the true tumor size better than GTD and we reported that TV can provide more prognostic information than GTD in patients with stage I-III NSCLC after complete resection.

      Abstract

      Aim

      The aim of this study was to investigate the prognostic impact of tumor volume (TV, recorded from surgical specimens) on patients with stage I-III non-small cell lung cancer (NSCLC) after complete resection.

      Methods

      129 patients with stage I-III NSCLC diagnosed and underwent curative resection from 2007 to 2014 in our center were included in the study. Their clinico-pathological factors were retrospectively reviewed. Overall survival (OS) and disease-free survival (DFS) analyses were performed with the Kaplan-Meier method and Cox's hazard model. According to the ROC analysis, patients were divided into two groups (Group 1: 58patients < 30.3 cm3 and Group 2: 71 patients ≥ 30.3 cm3) and the OS and DFS values were compared.

      Results

      Median TVs and greatest tumor diameter (GTD) were 12 cm3 (0.1-30) / 3cm (0.4-6.5) in Group 1 and 98 cm3 (30.6-1521) / 6 cm (3.5-21) in Group 2. Median OS was 53 (5-177) months in Group 1 and 38 (2-200) months in Group 2 (p<0.001). DFS was similar in both group [28 (1-140) vs 24 (1-155) months, p=0,489]. Kaplan-Meier curves showed significantly higher OS rates in Group 1 than Group 2 (p=0.04). In multivariable analysis (TV, tumor T stage, tumor N stage, receiving adjuvant radiotherapy) showed that TV (HR: 0.293, 95% CI: 0.121–0.707, p = 0.006) and tumor N stage (HR: 0.013, 95% CI:0.001-0.191, p=0.02) were independent factors associated with OS.

      Conclusion

      Tumor volume, not considered in the routine TNM classification, may improve prediction accuracy of overall OS in operated Stage I-III NSCLC.

      Micro Abstract

      Tumor volume (TV), not considered in the routine TNM classification, may improve prediction accuracy of overall survival (OS) and disease free survival (DFS) in operated stage I-III non-small cell lung cancer (NSCLC). 129 patients with NSCLC diagnosed and underwent curative resection were examined and TV was independent factor for OS and DFS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goldstraw P
        • Chansky K
        • Crowley J
        • et al.
        International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
        J Thorac Oncol. 2016 Jan; 11 (PMID: 26762738): 39-51https://doi.org/10.1016/j.jtho.2015.09.009
        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2016.
        CA: A Cancer Journal for Clinicians. 2016; 66: 7-30https://doi.org/10.3322/caac.21332
        • Edge S.B
        • Byrd D.R
        • Compton C.C
        • et al.
        AJCC Cancer Staging Manual.
        7th ed. Springer, New York2010
        • Rami-Porta R
        • Bolejack V
        • Crowley J
        • et al.
        The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.
        J Thorac Oncol. 2015; 10: 990-1003https://doi.org/10.1097/JTO.0000000000000559
        • Patz Jr., EF
        • Rossi S
        • Harpole Jr., DH
        • et al.
        Correlations of tumor size and survival in patients with stage 1A non-small cell lung cancer.
        Chest. 2000; 117: 1568-1571https://doi.org/10.1378/chest.117.6.1568
        • Tsoukalas N
        • Mosa E
        • Tsapakidis K
        • et al.
        Primary Gross Tumor Volume (pGTV) and Tumor Response in Locally Advanced Rectal Cancer (LARC). Is There Any Correlation?.
        J Invest Surg. 2021 Feb; 34 (Epub 2019 Aug 19. PMID: 31423856): 191-193https://doi.org/10.1080/08941939.2019.1650988
        • Hida T
        • Dahlberg SE
        • Lydon CA
        • et al.
        Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.
        J Thorac Imaging. 2020 Mar; 35 (PMID: 30985604): 101-107https://doi.org/10.1097/RTI.0000000000000413
        • Jia B
        • Zhang X
        • Mo Y
        • et al.
        The Study of Tumor Volume as a Prognostic Factor in T Staging System for Non-Small Cell Lung Cancer: An Exploratory Study.
        Technol Cancer Res Treat. 2020 Jan-Dec; 19 (PMID: 33297855; PMCID: PMC7734535)1533033820980106https://doi.org/10.1177/1533033820980106
        • Greene FL
        • Page DL
        • Fleming ID.
        AJCC cancer staging manual.
        6th ed. Springer-Verlag, New York2002
        • Travis WD
        • Brambilla E
        • Muller-Hermelink HK
        • et al.
        Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, World Health Organization Classification of Tumours.
        IARC – Press, Lyon, France2004
        • Port JL
        • Kent MS
        • Korst RJ
        • et al.
        Tumor size predicts survival within stage IA non-small cell lung cancer.
        Chest. 2003; 124 (PMID: 14605056): 1828-1833https://doi.org/10.1378/chest.124.5.1828
        • Yanagi S
        • Sugiura H
        • Morikawa T
        • et al.
        Tumor size does not have prognostic significance in stage Ia NSCLC.
        Anticancer Res. 2000; 20 (PMID: 10810413): 1155-1168
        • Castro PP
        • de Perrot M
        • Chua YC
        • et al.
        Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
        J Thorac Cardiovasc Surg. 2022; 164 (Epub 2022 Feb 11): 629-636https://doi.org/10.1016/j.jtcvs.2022.02.015
        • Zhang J
        • Gold KA
        • Lin HY
        • et al.
        Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.
        J Thorac Oncol. 2015; 10: 682-690https://doi.org/10.1097/JTO.0000000000000456
        • Yang D
        • Liu Y
        • Bai C
        • et al.
        Epidemiology of lung cancer and lung cancer screening programs in China and the United States.
        Cancer Lett. 2020 Jan 1; 468 (Epub 2019 Oct 7. PMID: 31600530): 82-87https://doi.org/10.1016/j.canlet.2019.10.009
        • Xiao L
        • Lin Q
        • Hu M
        • et al.
        Could intracranial tumor volume predict prognosis of patients with brain metastases from esophageal carcinoma?.
        Thorac Cancer. 2022 Apr; 13 (Epub 2022 Mar 15. PMID: 35289101; PMCID: PMC9013658): 1193-1198https://doi.org/10.1111/1759-7714.14384
        • Seifert R
        • Kessel K
        • Schlack K
        • et al.
        PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.
        Eur J Nucl Med Mol Imaging. 2021; 48: 1200-1210https://doi.org/10.1007/s00259-020-05040-1
        • Narayan K
        • Fisher R
        • Bernshaw D.
        Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy.
        Int J Gynecol Cancer. 2006 Mar-Apr; 16 (PMID: 16681737): 623-630https://doi.org/10.1111/j.1525-1438.2006.00379.x
        • Rutkowski T.
        The role of tumor volume in radiotherapy of patients with head and neck cancer.
        Radiat Oncol. 2014 Jan 14; 9: 23https://doi.org/10.1186/1748-717X-9-23
        • Takenaka T
        • Yamazaki K
        • Miura N
        • et al.
        The Prognostic Impact of Tumor Volume in Patients with Clinical Stage IA Non-Small Cell Lung Cancer.
        J Thorac Oncol. 2016 Jul; 11: 1074-1080https://doi.org/10.1016/j.jtho.2016.02.005
        • Su XD
        • Xie HJ
        • Liu QW
        • et al.
        The prognostic impact of tumor volume on stage I non-small cell lung cancer.
        Lung Cancer. 2017; 104: 91-97https://doi.org/10.1016/j.lungcan.2016.12.013
        • Tsai CH
        • Lin CM
        • Hsieh CC
        • et al.
        Tumor volume is a better prognostic factor than greatest tumor diameter in stage Ia non-small cell lung cancer.
        Thorac Cardiovasc Surg. 2006; 54: 537-543https://doi.org/10.1055/s-2006-924479
        • Dehing-Oberije C
        • De Ruysscher D
        • van der Weide H
        • et al.
        Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
        Int J Radiat Oncol Biol Phys. 2008; 70: 1039-1044https://doi.org/10.1016/j.ijrobp.2007.07.2323
        • Mozley PD
        • Bendtsen C
        • Zhao B
        • et al.
        Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer.
        Transl Oncol. 2012; 5 (PMID: 22348172; PMCID: PMC3281412): 19-25https://doi.org/10.1593/tlo.11232
        • Ball DL
        • Fisher RJ
        • Burmeister BH
        • et al.
        The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05).
        Radiother Oncol. 2013; 106 (PMID: 23333017): 305-311https://doi.org/10.1016/j.radonc.2012.12.003
        • Kanzaki H
        • Kataoka M
        • Nishikawa A
        • et al.
        Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy.
        Int J Clin Oncol. 2016 Oct; 21: 853-861https://doi.org/10.1007/s10147-016-0982-0
        • Werner-Wasik M
        • Swann RS
        • Bradley J
        • et al.
        Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2008 Feb 1; 70: 385-390https://doi.org/10.1016/j.ijrobp.2007.06.034
        • Tarsitano A
        • Ricotta F
        • Cercenelli L
        • et al.
        Pretreatment tumor volume and tumor sphericity as prognostic factors in patients with oral cavity squamous cell carcinoma.
        J Craniomaxillofac Surg. 2019 Mar; 47: 510-515https://doi.org/10.1016/j.jcms.2018.12.019
        • van Bockel LW
        • Monninkhof EM
        • Pameijer FA
        • et al.
        Importance of tumor volume in supraglottic and glottic laryngeal carcinoma.
        Strahlenther Onkol. 2013 Dec; 189: 1009-1014https://doi.org/10.1007/s00066-013-0467-2